NovaBridge Biosciences

Diversified biologics

NBP · Nasdaq · China / United States

Share price · NBP

$0.90-0.99 (-52.22%) 3M

close as of 2026-11-18 · 24h delayed · vol 874K (1.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when NBP's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Nov 2026+9.8%
  2. 3 Nov 2026-5.6%
  3. 2 Nov 2026-10.5%
  4. 26 Oct 2026-11.3%
  5. 20 Oct 2026+9.6%
  6. 24 Sep 2026-5.2%
  7. 29 Jun 2026+20.7%
  8. 6 May 2026-5.5%
  9. 30 Mar 2026-11.8%
  10. 5 Mar 2026+17.0%

Share of unusual movement by asset

For each asset, the share of NBP's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
givastomig
events and moves
1814%
Other company news (earnings, financing, releases naming no asset)—27%
Sessions with no dated event—59%

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2/3
CD73Monoclonal antibody
Non-Small Cell Lung Cancer
Phase 2
Claudin 18.2 (CLDN18.2) x 4-1BBMultispecific antibody
Gastric Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
August 2028 (1)
UliledlimabPhase 2/3Non Small Cell Lung Cancer
Est. primary completion 2028-08-05 · NCT06984588 · CT.gov ↗
What to watch
2030 (1)
March 2030 (1)
givastomigPhase 2Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer, Gastroesophageal Junction Carcinoma, Esophageal Adenocarcinoma
Est. primary completion 2030-03 · NCT07432295 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (7)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q2$0$3.3M$166M$5.5Mreport ↗

NovaBridge Biosciences reported revenue of $0M for 2025-Q2, with R&D spend of $3.3M, down 69.4% YoY. Cash and equivalents stood at $165.6M, while net income/loss was not disclosed and quarterly net burn was $5.5M. No analyst consensus comparison was provided.

The material disclosed no financial guidance or pipeline/clinical developments. The key event was a proposed change of the company’s name from I-Mab to NovaBridge Biosciences, along with the adoption of a seventh amended and restated memorandum and articles of association, to be voted on at an extraordinary general meeting on October 24, 2025.

View 6 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q1$0$0.8M$169M$3.2Mreport ↗
2024-Q3$0$4.5M$184M$20Mreport ↗
2024-H1$0$11M$208M—report ↗
2023-H1$2.7M$62M$415M$107Mreport ↗
2022-H1$7.7M$68M$586M$156Mreport ↗
2021-H1$2.8M$92M$739M$167Mreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$63M$211M—report ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$22M$173M$22Mreport ↗
2023-FY$3.9M$115M$310M+ $20M short-term inv.$52Mreport ↗
2022-FY-$33M$135M$475M+ $34M short-term inv.$93Mreport ↗
2021-FY$14M$188M$553M+ $118M short-term inv.$90Mreport ↗

Insider transactions

Open-market activity, trailing 12 months: 3 purchases ($663K), 7 sales ($154K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-18Hagler Mark Arnold · Chief Commercial OfficerOpen-market purchase184,000$0.38$70KForm 4
2026-11-17Hagler Mark Arnold · Chief Commercial OfficerOpen-market purchase46,000$0.34$16KForm 4
2026-10-15Woo Ian Ying · directorOption exercise13,271——Form 4
2026-10-15Woo Ian Ying · directorOption exercise (derivative)5,770——Form 4
2026-09-18Dennis Phillip Andrew · Chief Medical OfficerOpen-market sale8,209$0.71$6KForm 4
2026-09-17Dennis Phillip Andrew · Chief Medical OfficerOption exercise23,695——Form 4
2026-09-17Dennis Phillip Andrew · Chief Medical OfficerOption exercise (derivative)10,302——Form 4
2026-09-09Cao Sean Wuxiong · Chief Bus. Development OfficerOpen-market sale107,978$0.74$80KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 48 reporting institutions held 29.3M shares ($71.8M, 25.4% of shares outstanding).

#InstitutionSharesValue
1JANUS HENDERSON GROUP PLC6,032,650$14.8M
2HHLR ADVISORS, LTD.5,980,568$14.7M
3MORGAN STANLEY3,838,198$9.4M
4Siren, L.L.C.3,000,000$7.4M
5AIHC Capital Management Ltd2,262,933$5.6M
6Point72 Asset Management, L.P.1,389,403$3.4M
7Candriam S.C.A.1,132,563$2.8M
8ADAGE CAPITAL PARTNERS GP, L.L.C.1,000,000$2.5M
9Woodline Partners LP700,000$1.7M
10BlackRock, Inc.627,496$1.5M
11Exome Asset Management LLC576,960$1.4M
12STATE STREET CORP370,107$910K
13Fiera Capital Corp315,681$777K
14BARCLAYS PLC299,299$736K
15RENAISSANCE TECHNOLOGIES LLC272,412$670K